EP0769939A1 - Utilisation d'inhibiteurs de s-cd23 humaine - Google Patents

Utilisation d'inhibiteurs de s-cd23 humaine

Info

Publication number
EP0769939A1
EP0769939A1 EP95943503A EP95943503A EP0769939A1 EP 0769939 A1 EP0769939 A1 EP 0769939A1 EP 95943503 A EP95943503 A EP 95943503A EP 95943503 A EP95943503 A EP 95943503A EP 0769939 A1 EP0769939 A1 EP 0769939A1
Authority
EP
European Patent Office
Prior art keywords
inhibitor
human
formation
prophylaxis
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP95943503A
Other languages
German (de)
English (en)
Inventor
Gary Christie
Beverley Jane Weston
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of EP0769939A1 publication Critical patent/EP0769939A1/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • This invention relates to a medical use and in particular to the use of inhibitors of the formation of soluble human CD23 for the treatment of conditions associated with excess production of soluble CD23 (s-CD23) such as autoimmune disease and allergy.
  • s-CD23 soluble CD23
  • Matrix metalloproteases such as coUagenase, stromelysin and gelatinase are known to be involved in connective tissue breakdown.
  • matrix metalloprotease inhibitors include derivatives of hydroxamic acid, phosphonates and Lhiols.
  • WO 93/20047 discloses various derivatives of hydroxamic acid including those from the following patent publications: USP 4599361, EP-A-0236872, EP-A- 0274453, WO 90/05716, WO 90/05719, WO 91/02716, EP-A-0489577, EP-A- 0489579, EP-A-0497192 and WO 92/13831.
  • CD23 (the low affinity IgE receptor Fc ⁇ RH, Blast 2), is a 45 kDa type ⁇ integral protein expressed on the surface of a variety of mature cells, including B and T lymphocytes, macrophages, natural killer cells, Langerhans cells, monocytes and platelets (Delespesse et al, Adv Immunol, 42 [1991] 149-191). There is also a CD23- like molecule on eosinophils (Grangette et al, J Immunol, 142 [1989] 3580-3588). CD23 has been implicated in the regulation of the immune response (Delespesse et al, Immunol Rev, 125 [1992] 77-97).
  • Human CD23 exists as two differentially regulated isoforms, a and b, which differ only in the amino acids at the intracellular N-terminus (Yokota et al. Cell, U [1988] 611-618). In man the a isoform is found only on B- lymphocytes, whereas type b is found on all other cells capable of expressing CD23. However, expression of the b isoform on B-lymphocytes is inducible by IL4.
  • i-CD23 cell bound CD23
  • S-CD23 well-defined soluble fragments
  • S-CD23 has been implicated in the overproduction of IgE, the hallmark of allergic diseases such as extrinsic asthma, rhinitis, allergic conjuctivitis, eczema, atopic dermatitis and anaphylaxis (Sutton and Gould, Nature, 2 ⁇ & [1993] 421-428).
  • Other biological activities attributed to S-CD23 include the stimulation of B cell growth and the induction of the release of mediators from monocytes.
  • S-CD23 serum of patients having B-chronic lymphocytic leukaemia (Sarfati et al, Blood, 21 [1988] 94-98) and in the synovial fluids of patients with rheumatoid arthritis (Chomarat et al, Arthritis and Rheumatism, _ [1993] 234-242).
  • compounds which inhibit the formation of S-CD23 should have twofold actions of a) enhancing negative feedback inhibition of IgE synthesis by maintaining levels of i-CD23 on the surface of B cells, and b) inhibiting the immunostimulatory cytokine activities of higher molecular weight soluble fragments (Mr 37, 33 and 29 kDa) of S-CD23. It has now surprisingly been found that compounds which inhibit the action of matrix metalloproteases (eg coUagenase, stromelysin and gelatinase) are effective inhibitors of the release of human soluble CD23 transfected into mammalian cell culture systems.
  • matrix metalloproteases eg coUagenase, stromelysin and gelatinase
  • Inhibitors of the matrix metalloproteases are therefore potentially useful for the treatment or prophylaxis of disorders such as allergy and autoimmune disease in which the overproduction of S-CD23 is implicated.
  • matrix metalloprotease inhibitors include derivatives of hydroxamic acid, phosphonic acid and thiols, all of which have been shown to inhibit CD23 proteolysis.
  • the present invention provides the use of an inhibitor of the formation of human soluble CD23, such as an inhibitor of matrix metalloproteases, for the production of a medicament for the treatment or prophylaxis of disorders such as allergy and autoimmune disease in which the overproduction of S-CD23 is implicated.
  • the invention provides a method for the treatment or prophylaxis of disorders such as allergy and autoimmune disease in which the overproduction of S-CD23 is implicated, which method comprises the administration of an inhibitor of the formation of soluble human CD23, such as an inhibitor of matrix metalloproteases, to a human or non-human mammal in need thereof.
  • the invention also provides a pharmaceutical composition for the treatment or prophylaxis of disorders such as allergy and autoimmune disease in which the overproduction of S-CD23 is implicated which comprises an inhibitor of the formation of soluble human CD23, such as an inhibitor of matrix metalloproteases and optionally a pharmaceutically acceptable carrier therefor.
  • Suitable matrix metalloprotease inhibitors are set out in the Table and include the hydroxamic acid derivatives disclosed in WO 90/05716, WO 90/05719, WO 91/02716. WO 92/13831, WO 93/20047, EP-A-0236872, EP-A-0274453, EP-A- 0489577, EP-A-0489579, EP-A-0497192 and USP 4599361. Suitable matrix metalloprotease inhibitors also include the thiols and phosphonic acids disclosed in EP 273689 and EP320118.
  • Particular matrix metalloprotease inhibitors include the compounds disclosed hereinafter in the Procedures section.
  • Favoured matrix metalloprotease inhibitors include Example 2 of WO 90/05719 and Example 1 of EP 0497192.
  • the matrix metalloprotease inhibitors mentioned herein may exist in several different isomeric forms, including stereoisomeric forms. Unless specifically stated to the contrary herein with respect to particular compounds, all isomers including stereoisomers and mixtures of isomers, such as racemic mixtures, are included within the present invention.
  • the matrix metalloprotease inhibitors of the invention may be prepared by use of any appronate conventional method, for example the matrix metalloprotease inhibitors disclosed in patent publications WO 90/05716, WO 90/05719, WO 91/02716, WO 92 13831, WO 93/20047, EP-A-0236872, EP-A-0274453, EP-A- 0489577, EP-A-0489579, EP-A-0497192 and USP 4599361, EP 273689 and EP320118 may be prepared by the methods disclosed therein.
  • the isomers, including stereoisomers, of the matrix metalloprotease inhibitors of the present invention may be prepared as mixtures of such isomers or as individual isomers.
  • the individual isomers may be prepared by any appropriate method, for example individual stereoisomers may be prepared by stereospecific chemical synthesis starting from chiral substrates or by separating mixtures of enantiomers using known methods.
  • matrix metalloprotease inhibitors are isolated in substantially pure form.
  • matrix metalloprotease inhibitor and equivalent terms means any compound which inhibits any member of the family of zinc and calcium dependent endopeptidases (matrix metalloproteases) that have the ability to degrade components of the connective tissue matrices. Matrix metalloproteases and their inhibition are discussed by inter alia Hooper, FEBS Letters 1994, 354,1-6; Gordon et al., Clinical and Experimental Rheumatology 1993, 1 KSuppl. 8), S91-S94; Woessner, FASEB 1991, 5, 2145-2154; and Birkedal-Hansen, Critical Reviews in Oral Biology and Medicine 1993, 4(2), 197-250.
  • an inhibitor of the formation of soluble human CD23 such as a matrix metalloprotease inhibitor, has useful medical properties.
  • the active compounds are administered as pharmaceuticaUy acceptable compositions.
  • compositions are preferably adapted for oral administration. However, they may be adapted for other modes of administration, for example in the form of a spray, aerosol or other conventional method for inhalation, for treating respiratory tract disorders; or parenteral administration for patients suffering from heart failure. Other alternative modes of administration include sublingual or transdermal administration.
  • compositions may be in the form of tablets, capsules, powders, granules, lozenges, suppositories, reconstitutable powders, or liquid preparations, such as oral or sterile parenteral solutions or suspensions.
  • a composition of the invention is in the form of a unit dose.
  • Unit dose presentation forms for oral administration may be tablets and capsules and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone; fillers, for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tabletting lubricants, for example magnesium stearate; disintegrants, for example starch, polyvinylpyrrolidone, sodium starch glycoUate or microcrystalline cellulose; or pharmaceutically acceptable wetting agents such as sodium lauryl sulphate.
  • binding agents for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone
  • fillers for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine
  • tabletting lubricants for example magnesium stearate
  • disintegrants for example star
  • the solid oral compositions may be prepared by conventional methods of blending, filling or tabletting. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fiUers. Such operations are of course conventional in the art
  • the tablets may be coated according to methods weU known in normal pharmaceutical practice, in particular with an enteric coating.
  • Oral liquid preparations may be in the form of, for example, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use.
  • Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl ceUulose, gelatin, hydroxyethylceUulose, carboxymethylceUulose, aluminium stearate gel, hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, fractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid; and if desired conventional flavouring or colouring agents.
  • suspending agents for example sorbitol
  • fluid unit dosage forms are prepared utilizing the compound and a sterile vehicle, and, depending on the concentration used, can be either suspended or dissolved in the vehicle.
  • the compound can be dissolved in water for injection and filter sterilized before filling into a suitable vial or ampoule and sealing.
  • adjuvants such as a local anaesthetic, a preservative and buffering agents can be dissolved in the vehicle.
  • the composition can be frozen after filling into the vial and the water removed under vacuum.
  • Parenteral suspensions are prepared in substantially the same manner, except that the compound is suspended in the vehicle instead of being dissolved, and sterilization cannot be accomplished by filtration.
  • the compound can be sterilized by exposure to ethylene oxide before suspending in the sterile vehicle.
  • a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.
  • compositions of this invention may also suitably be presented for administration to the respiratory tract as a snuff or an aerosol or solution for a nebulizer, or as a microfine powder for insufflation, alone or in combination with an inert carrier such as lactose.
  • the particles of active compound suitably have diameters of less than 50 microns, preferably less than 10 microns for example diameters in the range of 1-50 microns, 1-10 microns or 1-5 microns.
  • compositions may contain from 0.1% to 99% by weight, preferably from 10-60% by weight, of the active material, depending upon the method of administration.
  • a preferred range for inhaled administration is 10-99%, especiaUy 60-99%, for example 90, 95 or 99%.
  • Microfine powder formulations may suitably be administered in an aerosol as a metered dose or by means of a suitable breath-activated device.
  • Suitable metered dose aerosol formulations comprise conventional propellants, cosolvents, such as ethanol, surfactants such as oleyl alcohol, lubricants such as oleyl alcohol, desiccants such as calcium sulphate and density modifiers such as sodium chloride.
  • Suitable solutions for a nebulizer are isotonic sterilised solutions, optionally buffered, at for example between pH 4-7, containing up to 20mg/ml of compound but more generally 0.1 to lOmg/ml, for use with standard nebulisation equipment
  • a unit dose form of a composition of the invention may contain from 0.1 to lOOOmg of a compound of the invention (0.001 to lOmg via inhalation) and more usually from 1 to 500mg, for example 1 to 25 or 5 to 500mg.
  • Such compositions may be administered from 1 to 6 times a day, more usually from 2 to 4 times a day, in a manner such that the daily dose is from lmg to lg for a 70 kg human adult and more particularly from 5 to 500mg. That is in the range of about 1.4 x ⁇ 0 ⁇ - mg/kg/day to 14 mg/kg/day and more particularly in the range of about 7 x 10"2 mg/kg day to 7 rag kg/day.
  • Procedure 1 The ability of test compounds to inhibit the release of soluble CD23 was investigated by use of the following procedure.
  • Adherent Chinese Hamster Ovary cells which had been transfected with the alpha form of CD23 were grown in microtitre plates. CeUs were grown to confluence in ⁇ -MEM medium with 10% foetal calf serum, 2mM glutamine containing 800 micro g/ml G418. Medium was removed and the cells washed with sterile phosphate buffered saline. Test compounds were dissolved in dimethyl sulphoxide at a stock concentration of 20mM, then dUuted 1 in 200 with ⁇ -MEM containing 800 micro g ml G418 (no foetal calf serum). 100ml of the diluted compounds were added to the adherent cells in triplicate weUs.
  • the average concentration (IC50) of test compound which inhibits the release of soluble CD23 by 50% relative to the control culture was determined.
  • test compounds to inhibit the formation of human IgE in vitro was investigated using the following procedure: Human peripheral blood mononuclear cells were separated by centrifugation over Ficoll-Paque (Pharmacia). The cells were suspended in RPMI 1640 medium containing 10% foetal calf serum, 2mM glutamine, 50 microM 2-mercaptoethanol and 50 micro g/ml gentamycin (TCM) at a concentration of 1.25 x 10 6 cells/ml. 800 micro 1 of the cell suspension were aliquoted into the weUs of a 48 weU plate.
  • TCM or IL4 100 micro 1 of TCM or IL4 at 500ng/ml was added in quadripUcate to the appropriate wells, followed by 100 micro 1 of TCM or lOx the final concentration of compound under investigation.
  • Test compounds are dissolved in dimethylsulphoxide (DMSO) at a stock dilution of 10" 2 M diluted 1 in 100 in TCM and then as above. The plates are incubated for 12 days at 37°C in a 95% air/5% CO2 humidified incubator. At the end of the culture period the supernatants were removed with the weUs and centrifuged (200xg for 10 minutes) to remove any non-adherent cells. There was no toxicity as assessed by trypan blue dye exclusion. The IgE concentration in the supernatants was measured by ELISA.
  • test compounds to inhibit the formation of human IgE in vitro was investigated using the following procedure:
  • Human tonsillar B lymphocytes were suspended in RPMI 1640 medium containing 10% foetal calf serum, 2mM glutamine, 50 micro M 2-mercaptoethanol and 50 micro g/ml gentamycin (TCM) at a concentration of 1.25 x 10 6 cells/ml. 800 micro 1 of the cell suspension were aliquoted into the wells of a 48 well plate. 100 micro 1 of TCM or IL4 at lOOng/ml and antibody to CD40 at 10 microg/ml was added in quadripUcate to the appropriate wells, followed by
  • Test compounds are dissolved in DMSO at a stock dilution of 10 ⁇ ⁇ M diluted 1 in 100 in TCM and then as above. The plates are incubated for 11 days at 37°C in a 95% air/5% CO2 humidified incubator. At the end of the culture period the supernatents were removed from the wells and centrifuged (200xg for 10 minutes) to remove any non-adherent cells. There was no toxicity as assessed by trypan dye exclusion. The IgE concentration in the supernatants was measured by ELISA.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Des inhibiteurs de métalloprotéases matricielles telles que la collagénase sont capables d'inhiber la libération de CD23 soluble humaine et sont par conséquent utiles en thérapie et en prophylaxie d'états caractérisés par un excès de CD23 soluble, tels que l'allergie et les maladies auto-immunitaires.
EP95943503A 1994-07-13 1995-07-07 Utilisation d'inhibiteurs de s-cd23 humaine Ceased EP0769939A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9414157 1994-07-13
GB9414157A GB9414157D0 (en) 1994-07-13 1994-07-13 Medical use
PCT/EP1995/002693 WO1996002240A2 (fr) 1994-07-13 1995-07-07 Utilisation d'inhibiteurs de s-cd23 humaine

Publications (1)

Publication Number Publication Date
EP0769939A1 true EP0769939A1 (fr) 1997-05-02

Family

ID=10758281

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95943503A Ceased EP0769939A1 (fr) 1994-07-13 1995-07-07 Utilisation d'inhibiteurs de s-cd23 humaine

Country Status (4)

Country Link
EP (1) EP0769939A1 (fr)
JP (1) JPH10502656A (fr)
GB (1) GB9414157D0 (fr)
WO (1) WO1996002240A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9601042D0 (en) * 1996-01-17 1996-03-20 Smithkline Beecham Plc Medical use
US6548084B2 (en) 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
GB9609795D0 (en) * 1996-05-10 1996-07-17 Smithkline Beecham Plc Novel compounds
GB9609794D0 (en) 1996-05-10 1996-07-17 Smithkline Beecham Plc Novel compounds
GB9706255D0 (en) * 1997-03-26 1997-05-14 Smithkline Beecham Plc Novel compounds
GB9813451D0 (en) * 1998-06-22 1998-08-19 Smithkline Beecham Plc Novel compounds
CN1313776A (zh) * 1998-07-17 2001-09-19 富士药品工业株式会社 变态反应性疾病治疗药物
KR20010083122A (ko) * 1998-07-17 2001-08-31 추후제출 신규한 알레르기 질환 치료제
GB9929527D0 (en) * 1999-12-14 2000-02-09 Smithkline Beecham Plc Novel compounds
GB9930754D0 (en) * 1999-12-29 2000-02-16 Smithkline Beecham Plc Novel compounds
US20030134880A1 (en) * 2000-02-24 2003-07-17 Gordon Bruton Novel cd23 inhibitors
EP1142910A1 (fr) * 2000-04-07 2001-10-10 Jürgen Prof. Dr. Frey Des inhibiteurs de la formation du facteur soluble humain CD23

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8827308D0 (en) * 1988-11-23 1988-12-29 British Bio Technology Compounds
GB8827305D0 (en) * 1988-11-23 1988-12-29 British Bio Technology Compounds
AU634533B2 (en) * 1989-03-21 1993-02-25 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Matrix metalloproteinase inhibitor peptides
GB9001625D0 (en) * 1990-01-24 1990-03-21 Ciba Geigy Ag A pharmaceutical preparation for maturation of prothymocytes
JPH06503642A (ja) * 1990-09-21 1994-04-21 ザ　ソーク　インスティテュート　フォア　バイオロジカル　スタディーズ プロトオンコタンパク質ｃ−ＪＵＮとホルモン受容体との間の機能的拮抗作用
JPH06506202A (ja) * 1991-03-22 1994-07-14 ゼノバ　リミテッド 医薬用キサントン誘導体
KR930002833A (ko) * 1991-07-08 1993-02-23 강석재 전기 회로의 끊어짐 점검장치
GB2280439B (en) * 1992-03-11 1995-11-22 Xenova Ltd CD4 binding agents and inhibitors of collagenase and protein kinase C
EP0634998B1 (fr) * 1992-04-07 1997-03-19 British Biotech Pharmaceuticals Limited Inhibiteurs de la collagenase et de la cytokine a base d'acide hydroxamique
GB9223904D0 (en) * 1992-11-13 1993-01-06 British Bio Technology Inhibition of cytokine production
CA2158352A1 (fr) * 1993-03-16 1994-09-29 Michael John Crimmin Derives de l'acide hydroxamique utilises comme inhibiteurs de la metalloproteinase
GB9307956D0 (en) * 1993-04-17 1993-06-02 Walls Alan J Hydroxamic acid derivatives
GB9320660D0 (en) * 1993-10-07 1993-11-24 British Bio Technology Inhibition of cytokine production
GB9323165D0 (en) * 1993-11-10 1994-01-05 Chiros Ltd Compounds
EP0822186B1 (fr) * 1994-01-20 2000-03-15 British Biotech Pharmaceuticals Limited L-tertiaire-leucine-2-pyridylamide
GB9401129D0 (en) * 1994-01-21 1994-03-16 British Bio Technology Hydroxamic acid derivatives as metalloproteinase inhibitors
KR970700652A (ko) * 1994-01-22 1997-02-12 포올 리틀우드 금속단백질 분해효소 억제제

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9602240A2 *

Also Published As

Publication number Publication date
GB9414157D0 (en) 1994-08-31
JPH10502656A (ja) 1998-03-10
WO1996002240A2 (fr) 1996-02-01
WO1996002240A3 (fr) 1997-02-13

Similar Documents

Publication Publication Date Title
US6242467B1 (en) Compounds
WO1996002240A2 (fr) Utilisation d'inhibiteurs de s-cd23 humaine
US6235753B1 (en) Inhibitors of the production of S-CD23 and the secretion of TNF
WO2021066144A1 (fr) Médicament pharmaceutique contenant un dérivé d'hétérocyclidène acétamide
EP1224164B1 (fr) Derive d'acide hydroxamique en tant qu'inhibiteur de formation du cd23 soluble humain
US20020082200A1 (en) Use of inhibitors of human S-CD23
EP0909169A1 (fr) Utilisation medicale
CZ222498A3 (cs) Inhibitor kolagenázy na bázi kyseliny hydroxamové, farmaceutický prostředek s jeho obsahem, způsob jeho přípravy a použití
EP0901464A1 (fr) Composes a base d'acide hydroxamique, inhibiteurs de la formation de cd23 et de facteur de necrose des tumeurs
WO2001022952A2 (fr) Utilisation medicale
EP1203583B1 (fr) Remedes contre la polyarthrite rhumatoide
EP3078372A1 (fr) Agent thérapeutique pour maladies sur la base de l'effet inhibiteur du facteur inhibiteur de migration macrophage (mif)
CN1224415A (zh) s－CD23产生和TNF分泌的抑制剂
CZ341799A3 (cs) Deriváty hydroxamové kyseliny substituované aryl- nebo heteroarylsulfonamidem, způsob jejich přípravy a jejich použití jako léčivých přípravků
CA2456965A1 (fr) Agent curatif pour arthrosis deformans

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19970108

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: SI PAYMENT 970108

17Q First examination report despatched

Effective date: 20010601

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SMITHKLINE BEECHAM PLC

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20040510